The financial terms of the agreement were not disclosed.
“We feel fortunate to be able to initiate this collaboration with a well-recognized institution like CHOP…This is an important step in further advancing and strengthening our [mitochondrial research] program, as well as in the development of novel treatment opportunities for people with mitochondrial medicine disorders,” said Magnus Hansson, CMO of NeuroVive.
More articles on transactions and valuations:
Ponder & Co: 2016 M&A activity down from last year
This week’s 3 most-read transactions and valuations stories
ECRI creates M&A service to help hospitals, health systems during transition
